Abstract Neoadjuvant chemotherapy has been shown to be equivalent to post-operative treatment for breast cancer, and allows for assessment of chemotherapy response. In a pilot trial of docetaxel (T) and capecitabine (X) neoadjuvant chemotherapy for Stage II/III BC, we assessed correlation between baseline gene expression and tumor response to treatment, and examined changes in gene expression associated with treatment. Patients received four cycles of TX. Tumor tissue obtained from Mammotome TM core biopsies pretreatment (BL) and post-cycle 1 (C1) of TX was flash frozen and stored at -70°C until processing. Gene expression analysis utilized Affymetrix HG-U133 Plus 2.0 GeneChip arrays. Statistical analysis was performed using BRB Array Tools after RMA normalization. Gene ontology (GO) pathway analysis used random variance t tests with a significance level of P \ 0.005. For gene categories identified by GO pathway analysis as significant, expression levels of individual genes within those pathways were compared between classes using univariate t tests; those genes with significance level of P \ 0.05 were reported. PAM50 analyses were performed on tumor samples to investigate biologic subtype and risk of relapse (ROR). Using GO pathway analysis, 39 gene categories discriminated between responders and non-responders, most notably genes involved in microtubule assembly and regulation. When comparing pre-and post-chemotherapy specimens, we identified 71 differentially expressed gene categories, including DNA repair and cell proliferation regulation. There were 45 GO pathways in which the change in expression after one cycle of chemotherapy was significantly different among responders and nonresponders. The majority of tumor samples fell into the basallike and luminal B categories. ROR scores decreased in response to chemotherapy; this change was more evident in Electronic supplementary material The online version of this article
Introduction
Breast cancer mortality has decreased over the last several decades, likely due to a combination of mammographic screening and improvements in systemic therapy [1] . A substantial proportion of women diagnosed with breast cancer in the United States receive adjuvant chemotherapy [2] , but our ability to predict a priori which patients are most likely to benefit from chemotherapy is limited. Recent advances in molecular profiling of tumor tissue suggest that a more personalized approach to breast cancer treatment may be possible [3, 4] . Trials that utilize pre-operative or neoadjuvant chemotherapy are uniquely situated to evaluate the molecular correlates of chemosensitivity because tumor response to treatment can be assessed in real time. These studies also have the added advantage of allowing the assessment of paired preand post-chemotherapy tumor specimens in order to better understand the biology and genetic heterogeneity of breast cancer. This could, in turn, lead to a more individualized approach to treatment-allowing for a specific selection of the chemotherapeutic agent or agents to which a particular tumor is most susceptible.
It is likely that the genes in which expression changes in response to chemotherapy are different among those who respond to therapy (i.e., genes conferring sensitivity) and those who do not (i.e., genes that confer resistance). In this study, we sought to identify genes associated with chemotherapy sensitivity and resistance. We utilized pre-and posttreatment biopsies from a phase II study of neoadjuvant docetaxel and capecitabine chemotherapy to assess the correlation between baseline gene expression and tumor response to treatment, and to examine changes in gene expression associated with treatment. We also sought to assess the accuracy of gene expression profiles identified in other studies as predictive of response in our dataset.
Materials and methods
The design of this phase II neoadjuvant treatment study has been previously described [5] . Briefly, women with newly diagnosed stage 2 or 3 breast cancer with a tumor size of C2 cm, normal laboratory parameters, and a Zubrod Performance status from 0 to 2 were eligible. Patients were excluded if they had a bleeding disorder, a history of cardiac disease, or if they were pregnant or lactating. The protocol was reviewed and approved by the Institutional Review Board of the National Cancer Institute.
All patients received four cycles of docetaxel and capecitabine administered every 21 days. Patients were initially treated with docetaxel (75 mg/m 2 i.v.) on day 1 and capecitabine (1,000 mg/m 2 p.o.) twice daily on days 2-15 every 21 days for four cycles. Due to excessive toxicity in the first 10 patients treated on protocol, both agents were dose reduced (docetaxel to 60 mg/m 2 and capecitabine to 937.5 mg/m 2 twice daily). After completing four cycles of docetaxel/capecitabine (TX), all patients received four cycles of adriamycin (60 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) on day 1 and every 21 days; six patients with a poor response to the initial chemotherapy received adriamycin and cyclophosphamide (AC) prior to surgery, the remainder had this additional therapy post-operatively. All tumor samples used in this analysis were taken prior to AC chemotherapy, and tumor measurements used to assess response were also taken prior to AC. Radiation therapy was individualized based on type of surgery, tumor size, and lymph node involvement. Patients with hormone receptor positive disease received either tamoxifen and/or an aromatase inhibitor after completing chemotherapy, surgery, and radiation treatment. No patients on this study received adjuvant or neoadjuvant trastuzumab.
We recorded tumor size using bidirectional and longest dimension measurements by physical examination at baseline, after completion of TX, and prior to surgery. We classified patients as either responders or non-responders based on change in tumor size by clinical exam and pathologic response (see Table 1 ). For patients treated pre-operatively with AC, response was assessed at the completion of TX. Briefly, patients with a pathological complete response (three patients), microinvasive disease at surgery (two patients), or clinical complete response after four cycles of TX (three patients) were considered as responders. All patients classified as responders received AC post-operatively. Thirteen patients were considered non-responders; 11 with a partial response (17-75% residual disease after four cycles of TX) and two with progressive disease (110-154% of baseline) after four cycles of TX. Of these, both patients with progressive disease and four patients with a partial response received additional pre-operative therapy with adriamycin and cyclophosphamide, however, the tumor measurements used to determine response category were taken prior to this additional treatment. All 21 patients are included in the baseline analysis, and 14 patients with paired baseline and post-cycle 1 evaluable specimens are included in the paired analyses (described in detail below). Tumors were assessed for estrogen (ER) and progesterone receptor (PgR) positivity by immunohistochemical staining using the 6F11 antibody for ER and clone 16 for PgR (Novocastra, US). Tumors were considered positive for ER or PgR if [1% of cells were positive. Tumors were considered HER2 positive if they were either categorized by the reading pathologist as 3? by immunohistochemistry (DAKO HercepTest) or if the HER2:CEP17 ratio by fluorescence in situ hybridization (FISH) was [2.0.
Tissue collection and processing
Tumor tissue was obtained by Mammotome TM biopsy prior to treatment, after one cycle of docetaxel/capecitabine chemotherapy, and from the definitive surgical specimen (OR). This report presents analyses using only baseline and postcycle 1 specimens, and thus the results of the gene expression analyses are not influenced by the receipt of adriamycin/ cyclophosphamide. Tissue was flash frozen with liquid nitrogen and stored at -70°C until processing. All samples included in the analysis were positive for malignant cells by hematoxylin and eosin staining on either formalin-fixed biopsy specimen (29%), touch prep (6%), or both (65%).
Total RNA was extracted from frozen tissues using TRIzol Ò Reagent (Life Technologies, Inc.) according to the standard protocol. The quantity and quality of the RNA was determined by the Agilent Technologies 2100 Bioanalyzer (Bio Sizing Software version A.02.01., Agilent Technologies) and the quantity determined with the Nanodrop Ò (Nanodrop Technologies). Samples containing high-quality total RNA with ratios between 1.8 and 2.1 were purified with the RNeasy Mini Kit (Qiagen) or the RNeasy Micro Kit (Qiagen), dependent on sample size. An ''on column'' digest was performed as part of this purification step using the RNase-Free DNase Set (Qiagen). Double-stranded cDNA was synthesized from this preparation using the GeneChip Ò Expression 3 0 -Amplification Two-Cycle cDNA Synthesis Kit according to the protocol for Affymetrix GeneChip Ò Eukaryotic Target Preparation. The resulting double-stranded cDNA was purified using the GeneChip Ò Sample Cleanup Module (Qiagen). Synthesis of Biotin-Labeled cRNA was obtained by in vitro transcription of the purified template cDNA using the GeneChip All assays were performed without knowledge of either class assignment (responder or non-responder) or time point of tumor sample obtainment.
Statistical analysis
Probe-level data were normalized and gene expression summaries were computed for each probe set using Robust Multichip Analysis (RMA). Statistical analyses were performed using BRB Array Tools version 3.4.1. All gene expression summary intensities (gene summaries) below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability (variance-based screening criteria) were screened out (P \ 0.01, based on v 2 test as implemented in BRB Array Tools [6] ).
Samples were clustered using agglomerative hierarchical clustering and using the mean centered 24,224 genes passing the variance-based screening with centered correlation as distance metric and average linkage as linkage function.
Gene Set Expression as implemented in BRB Array Tools was used to identify gene ontology (GO) groups that had more differentially expressed genes than expected by chance among [1] responders vs. non-responders and [2] baseline vs. post-cycle 1 specimens. Gene Set Expression method identifies which gene sets contain more differentially expressed genes than would be expected by chance using two statistics (LS and KS). We considered significant the GO categories for which the P value from the LS or KS permutation test was 0.005 or less. Each of the 24,224 genes passing the variance-based screening criteria could be mapped to more than one GO category. Overall, 1,666 GO categories were considered. Post-cycle 1 and baseline specimens were compared using methods for paired data.
In addition, we identified GO categories and genes in which the change in expression from baseline to post-cycle 1 was significantly different in responders vs. non-responders.
In order to perform this analysis, for each patient we calculated the log-ratios between post-cycle 1 and baseline gene summaries (thresholded as described above) and compared log-ratios between responders and non-responders; 19,165 genes passed the variance-based screening (applied to logratios and on this reduced set of samples) and 1,514 unique GO categories were considered.
In order to assess whether genes identified in other studies could predict response in our samples, we matched the 92 genes from the gene profile published by Chang et al. [7] to the probe sets of our array based on Locuslink ID, identifying 251 probe sets on the HG-U133 Plus 2.0 chip. A class predictor for response was developed using this set of genes on our data and its performance was assessed because the predictive model had to be partly re-developed on our data (only the gene list from previous study was kept fixed), its predictive accuracy was evaluated using leave-one-out cross-validation to avoid bias.
Finally, patient samples were also assessed using the PAM50 algorithm. For this analysis, raw data from baseline and post-cycle 1 specimens were processed using RMA normalization and each gene was centered to the training set median to account for array platform differences. Probesets were then mapped to Entrez gene names using the Affymetrix annotation file. Probesets that mapped to identical Entrez gene names were collapsed to the sample mean. The 50 genes of interest (listed in {Parker, 2009 #30}) were extracted and the Spearman's rank correlation between each sample and each subtype centroid was calculated. Each sample was assigned the class of the most highly correlated centroid. The algorithm outlined by Parker et al. [8] was followed to assign biologic subtype and risk of relapse (ROR) score.
Results

Patient and tumor characteristics
Patients were accrued to the study between January 2001 and August 2003. Thirty patients enrolled in the study; demographic and tumor characteristics for the entire study population have previously been described [5] . One patient withdrew after the first cycle of chemotherapy and was excluded from all analyses. Twenty-one patients had baseline tumor biopsies that contained malignant cells, and are included in the analysis of baseline gene expression in responders vs. non-responders (see Table 1 ). Of these, 14 patients had evaluable tumor samples at baseline and after one cycle of chemotherapy, and are included in subsequent analyses.
A clustering dendrogram of all tumor samples obtained is shown in Fig. 1 . In general, samples from the same patient at different time points clustered together. In addition, triple-negative tumors tended to cluster together, and hormone receptor positive tumors also clustered. Gene ontology (GO) category analysis
We compared gene expression in baseline specimens among responders and non-responders, and in baseline vs. postcycle 1 specimens, using GO categories, which describe gene products in terms of their associated biological processes, cellular components, and molecular functions. The analysis of baseline gene expression included baseline specimens from 21 patients: 8 responders and 13 nonresponders. Analyses of changes in gene expression included paired baseline and post-cycle 1 specimens from 14 patients; of these six patients were responders and eight patients were non-responders. When comparing responders with non-responders, 39 GO categories of 1,666 categories tested discriminated between the two groups at a significance level of P \ 0.005. On average, we would expect to find eight GO categories to be differentially expressed if there was no difference between classes. GO categories that were significantly differentially expressed are listed in Table 2 . The individual genes within these categories that showed differential expression (P \ 0.05) are listed in Appendix 1. These included a number of genes involved in regulation of microtubule depolymerization (microtubule-associated protein-2; MAP-2) and cell cycle arrest (microtubule-actin crosslinking factor 1; MACF1). Other genes of biologic interest that were differentially expressed included vascular endothelial growth factor-B (VEGF-B) and epidermal growth factor receptor (EGFR).
When comparing baseline tumor specimens with those obtained after one cycle of chemotherapy with docetaxel and capecitabine, 71 of 1,666 GO categories discriminated among classes at P \ 0.005 (Table 3) . On average, we would expect to find eight differentially expressed GO categories by chance alone. Individual genes that showed significantly different expression from these pathways are listed in Supplemental Appendix 2. Genes that were significantly differentially expressed included those involved in DNA repair [breast cancer 1 early onset; BRCA1, poly (ADP-ribose) polymerase family, member 2 and 3; PARP2 and PARP3)], and cell proliferation regulation [fibroblast growth factor receptor oncogene partner (FGFR1OP) and epidermal growth factor receptor (EGFR)]. In addition, a number of spindle-associated checkpoint genes exhibited differential expression including budding uninhibited by benzimidazoles proteins 1 and 3 (BUB1 and BUB3), mitotic arrest deficient protein 2L1 (MAD2L1), and tubulin isoform gamma.
We looked for which genes had a significantly different change in expression from baseline to post-cycle 1 between responders and non-responders. In this analysis, we found 45 of 1,514 GO categories (Table 4) in which the change in expression after one cycle of chemotherapy discriminated among the two classes (eight would be expected by chance alone). The individual genes within these categories that were statistically significantly different in this analysis are shown in Supplemental Appendix 3. Among the genes with greater changes in responders were two heat shock proteins (HSPA9B and HSPA5), inhibin beta-A, a number of ubiquitin-related genes, tumor necrosis factor alpha-induced protein 6 (TNFaIP6), and periostin (POSTN). Genes in which the change in expression was significantly greater in non-responders than in responders included transforming growth factor beta receptor III (TGFbR3), VEGFB, and fibroblast growth factor receptor-1 (FGFR1), and genes involved in reactive oxygen species metabolism such as glutathione peroxidase-3 (GPX3) and aldehyde oxidase-1 (AOX1).
Class prediction
In order to assess whether genes identified in other studies as important determinants of response to chemotherapy were predictive in our samples, we developed on our data set a class predictor for response using the genes identified by Chang et al. [7] and assessed its performance using leave-one-out cross-validation. The starting set of genes was the set of genes identified by Chang et al. [7] as significantly different between the classes of responders and non-responders in their data set. When developing our predictor we selected from among the Chang genes those that were significantly differentially expressed between classes at 0.1 significance level in our data set. In order to avoid introducing bias into the prediction accuracy estimate due to the use of our data for the classifier building process we used leave-one-out cross-validation. Specifically, the entire process of gene selection and model fitting was repeated for each leave-one-out cross-validation training set to ensure a fair representation of the prediction accuracy.
A compound covariate classifier for response had a sensitivity of 50% and a specificity of 61.5% estimated by cross-validation. Positive and negative predictive values were 44 and 67%, respectively. The cross-validated estimate of percent correct classification was 57%. Similar results were obtained using other prediction methods or further selecting the features to be included in the classifiers. Specifically, we restricted the analysis to the genes of Chang's list that showed a consistent ''direction'' in our data set, i.e., to the genes whose fold change between responders and non-responders was above or below 1 in both studies, regardless of the statistical significance in our data set. The predictive accuracy of the classifiers built using only concordant genes was similar to that noted above.
Biologic subtype and ROR score
Results of biologic subtype analysis and ROR scores are shown in Table 1 . At baseline, 38% of the 21 tumors analyzed were classified as basal-like, 29% were luminal B, 19% were luminal A, 9% were normal-like, and 5% were HER2-enriched. Luminal A tumors had the lowest ROR scores at baseline. The mean ROR was similar in responders and non-responders, although wider variation in baseline ROR was noted in non-responders (mean ROR in 
Discussion
In this study of gene expression by cDNA microarray analysis among breast cancer patients treated with neoadjuvant docetaxel and capecitabine, we identified a number of biologic pathways that appeared to be important in characterizing response to chemotherapy, including spindle regulation and microtubule depolymerization, DNA repair, and cellular proliferation. In addition, we found that previously published gene sets related to treatment response had modest predictive accuracy for our samples. Docetaxel is a taxane used to treat breast cancer in both the metastatic and adjuvant settings. Taxanes bind to tubulin and inhibit microtubule depolymerization, disrupting mitotic cell division and thus leading to cell death [9] . Microtubule-associated proteins, MAP2, MAP4, and MAPtau stabilize microtubules by binding to tubulin, and increased microtubule dynamics associated with altered MAP expression has been implicated in taxane resistance [10, 11] . In our study, non-responders had significantly higher expression of MAP2 than responders, suggesting that increased MAP2 protein may be involved in resistance in our patients. MAP4 was also among the genes in the GO pathways that showed a trend toward differential expression in our analysis, but the fold difference in gene expression between responders and non-responders was \2, and the P values for the individual gene probe sets corresponding to this gene were not statistically significant. In addition to these baseline differences, we saw changes in expression of a number of microtubule-and spindleassociated genes when comparing tumor specimens before and after one cycle of chemotherapy. These included spindle assembly checkpoint genes BUB1 and BUB3 and MAD2L1 and a number of tubulin isoforms. These genes may play also an important role in determining response to taxane containing chemotherapy.
We also noted significantly increased expression in a number of genes involved in the DNA repair pathway after one cycle of chemotherapy including BRCA1, PARP2, and CHEK1. DNA damage is the mechanism of action of many chemotherapeutic agents with activity in breast cancer, and alterations in DNA repair pathways are important in the pathogenesis of breast cancers associated with BRCA1 and BRCA2 mutations [12] . In addition, a new class of targeted agents, the PARP inhibitors, which inhibit a key enzyme involved in DNA repair, are being evaluated both as monotherapy for BRCA-associated cancers and in combination with DNA damaging agents [13, 14] . Given the known overlap between BRCA1 mutations and triplenegative tumors, these agents are also being evaluated in the setting of triple-negative disease (http://www.cancer. gov/search/ResultsClinicalTrialsAdvanced.aspx?protocol searchid=5122624). About a third of our study patients had triple-negative tumors, and a large percentage of responders in our study had triple-negative disease. The data from large neoadjuvant chemotherapy studies show that women with triple-negative tumors are more likely to achieve a pathologic complete response than those with hormone sensitive tumors, but those who do not respond have a poorer prognosis [15] . Thus, if DNA repair plays a key role in both the pathogenesis of these tumors, and in their response to treatment, as our data suggest, then the measurement of expression of these genes at the time of diagnosis and early in the course of chemotherapy may be both prognostic and predictive.
Genes in the FGF pathway have recently been shown in genome wide association studies to be related to risk of breast cancer [16, 17] , and tumor expression of FGF has been suggested to confer chemotherapy resistance, particularly resistance to paclitaxel [18, 19] . In our analysis, expression of FGFR1OP was significantly increased after one cycle of chemotherapy. The product of this gene is a centrosomal protein that is involved in the anchoring of microtubules, and has been implicated as a prognostic indicator in non-small cell lung cancer [20] . Also consistent with this hypothesis, FGFR1 gene expression decreased in responders in our analysis.
Genes thought to be involved in determining responsiveness to capecitabine, such as thymidylate synthetase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase [21] did not play a key role in our study. Pusztai et al. have recently suggested that small phase II studies are unlikely to identify individual genes that are significantly associated with response to individual therapeutic agents [22] . One obvious challenge is the lack of power in small studies combined with the problem of multiple comparisons, which makes it difficult to distinguish truly differentially expressed genes from noise. Alternatively, significant heterogeneity among tumors in these small studies could lead to the dilution of true differences in gene expression that might be apparent if more homogenous tumors were studied. Our patient population was quite heterogeneous with regard to molecular and histologic characteristics of the tumors. It is becoming increasingly apparent that different subclasses of breast cancer carry very different prognoses, and likely respond differently to particular classes of therapeutic agents. Thus, an analysis of changes in expression of DNA repair genes that is limited to triple-negative tumors may be more relevant to determining outcomes than that involving a mixed group of tumors.
The PAM50 analysis of our baseline specimens revealed a reasonable degree of agreement between ER and PgR expression and subtype classification, such that samples with ER or PgR expression by IHC tended to fall into the luminal categories, while triple-negative tumors expressed the basal phenotype. In addition, though the numbers are extremely small, the PAM50 analysis in paired pre-and post-chemotherapy specimens raises several interesting issues. First, we found that ROR scores generally decreased after one cycle of chemotherapy. This may reflect cell cycle arrest in response to chemotherapy. In addition, we saw that after one cycle of chemotherapy, the assigned phenotype for a majority of our specimens changed, with the most common change being from luminal B to luminal A subtype. These data could reflect a slowing of proliferation of tumor cells, rendering them more similar to the luminal A subtype. Alternatively, our data could reflect selective killing of tumor cells that are sensitive to chemotherapy, leaving a sub-population of hormone sensitive, less chemotherapy responsive tumor cells. While our results are biologically intuitive, these data must be interpreted with caution due to the small sample size and to methodological challenges in determining subtype membership on new data sets. One must be cautious in interpreting data from analyses in which mean centering of genes is used, particularly with small sample sizes and in cases where the subtype prevalence in the population being studied is different from that in the samples originally used to create the algorithm [23] . Re-assaying our samples using RT-PCR may have yielded different results, and may be helpful in future studies. Thus, larger studies with samples available for RT-PCR are needed to determine if a change in molecular subtype with chemotherapy is a true phenomenon with clinical implications. As previously noted, small phase II studies using high throughput analysis techniques can be limited by two important issues: a high false discovery rate due to the interrogation of a large number of genes, and significant heterogeneity in gene expression resulting in insufficient power to identify important individual genes. In our analysis, we attempted to overcome these potential problems by looking at biologically relevant gene pathways and categories rather than individual genes, and by using a previously designed categorization and scoring method based on multiple genes that has been shown to correlate with outcomes [8] . Our GO pathway analyses identified 39 GO categories that discriminated between responders and nonresponders, and 71 categories with significantly different expression after one cycle of chemotherapy out of a total of 1,666 categories containing genes that met the thresholding criteria. Using a P value of \0.005 for significance, we would expect that only eight categories would be significantly different for each of these analyses by chance alone. Skepticism regarding the ability of small phase II studies to identify pharmacogenomic markers of response to chemotherapy [22] is certainly warranted. However, we believe that performing analyses using biologically relevant pathways rather than individual genes is a viable strategy, especially for studies in which there is limited sensitivity for detecting significant differences in expression of individual genes. Thus, the pathway approach represents an important advance in the field of gene expression analysis.
Overall, our study has several distinct strengths. The availability of fresh frozen tissue collected at multiple time points over the course of treatment is a rare and valuable resource. Although we did not have paired samples on all study participants, we do not believe our study sample was biased. There did not appear to be any correlation between having pre-and post-chemotherapy specimens and tumor size, tumor characteristics or response to therapy.
However, several important limitations should be noted including the small sample size and lack of validation set for our findings. As a result, the data presented here must be considered exploratory. As we enter the era of individualized treatment in oncology, studies in which high quality tumor samples are obtained and stored for research and particularly for molecular diagnostics are crucial. In addition, neoadjuvant chemotherapy studies in which tumor samples taken before and after chemotherapy can be interrogated using novel molecular techniques are critical to advancing our understanding of both the biology of breast cancer, and of individual tumor responses to treatment.
In summary, we conclude that a number of biologically plausible pathways, including microtubule and cell spindle structure and function, DNA repair, and growth factor receptors may play a role in determining sensitivity and response to taxane-based chemotherapy. PAM50 analysis in our tumor specimens showed reasonable agreement between IHC classification and molecular subtype, as seen in other studies. In addition, our data suggest that tumor ROR scores decrease in response to chemotherapy, particularly in responsive tumors, although larger studies are necessary to confirm this finding. Gene pathway analysis using GO categories should be further examined as a means of limiting the false discovery rate of gene expression profiling studies. Further comparison of our findings with data from other investigators who examined the association between gene expression and response to therapy will be valuable in determining which particular genes are most important. Confirmation of these findings in larger studies with available tumor specimens will hopefully place us closer to realizing the goal of individualized therapy for breast cancer.
